Restarting Antiplatelet Therapy After Upper GI Bleeding

Aspirin Monotherapy for Secondary Cardiovascular Prevention

Aspirin for Primary Prevention

Dual Antiplatelet Therapy (DAPT) in Patients with Coronary Stents

Severity‑Based Management Approach

Life‑Threatening or Massive Upper GI Bleeding

Non‑Life‑Threatening Upper GI Bleeding

Risk Mitigation Strategies

Proton‑Pump Inhibitor Co‑Therapy

Outcomes of Permanent Antithrombotic Discontinuation

Comparative Benefit in Primary vs. Secondary Prevention

Timing for P2Y12 Inhibitor Resumption

Management of Aspirin in Acute GI Bleeding

Decision Algorithm for Aspirin Management in Acute GI Bleeding

• The American College of Cardiology recommends that aspirin for secondary cardiovascular prevention should not be routinely discontinued, but should be restarted as soon as hemostasis is achieved in patients with acute GI bleeding 2, 3
• Aspirin for primary prophylaxis of cardiovascular events should be permanently discontinued in patients with acute GI bleeding 4
• Aspirin for secondary prevention should be continued or restarted as soon as hemostasis is achieved in patients with established cardiovascular disease 2, 3

Severity-Based Management

• In patients with life-threatening or serious GI bleeding, aspirin should be temporarily withheld until initial hemostasis is achieved, and then restarted as soon as hemostasis is achieved 2, 3, 5, 6
• In patients with non-life-threatening GI bleeding, aspirin should be continued without interruption, especially in those with high cardiovascular risk 3, 7

Dual Antiplatelet Therapy (DAPT) Considerations

• If a patient is on DAPT, aspirin should be continued if possible, and the P2Y12 inhibitor should be temporarily withheld and restarted within 5 days maximum to prevent stent thrombosis 3, 5, 7, 8, 9

Evidence Supporting Continued/Early Restarted Aspirin

• Continuing aspirin after GI bleeding resulted in 10 times lower all-cause mortality compared to discontinuing aspirin, despite a numerically higher but non-significant rebleeding rate 7
• Discontinuation of aspirin therapy is associated with a threefold increased risk of major adverse cardiac events 2, 3
• Patients who discontinued aspirin after GI bleeding had almost sevenfold increased risk of death or acute cardiovascular events compared to those who continued therapy 7

Risk Mitigation Strategies

• A proton pump inhibitor (PPI) should always be initiated when restarting aspirin after GI bleeding 10
• The combination of aspirin with a PPI has been shown to be superior to clopidogrel alone for preventing recurrent bleeding 10
• For patients with coronary stents on DAPT, consultation with a cardiologist is recommended before making any changes to the antiplatelet regimen 3, 7

Important Caveats and Pitfalls

• Unnecessarily delaying aspirin resumption increases thrombotic risk, which can lead to higher mortality than the risk of rebleeding 2, 10
• Discontinuing both antiplatelet agents simultaneously in patients on DAPT can lead to stent thrombosis in as little as 7 days 7, 9
• Aspirin irreversibly inhibits platelet function for 5-7 days, so even short interruptions can increase thrombotic risk 4, 5
• The timing of restarting aspirin should balance the risk of rebleeding against the risk of thrombotic events 2, 3

Antiplatelet Therapy Resumption After Upper GI Bleeding

Immediate Aspirin Resumption for Secondary Prevention

• Restart aspirin on the same day that endoscopic hemostasis is confirmed in patients using aspirin for secondary cardiovascular prevention, together with high‑dose proton‑pump‑inhibitor therapy. This strategy reduces all‑cause mortality from 12.9 % to 1.3 % (≈10‑fold reduction). 11
• Continuing aspirin prevents a seven‑fold increase in the combined risk of death or acute cardiovascular events (hazard ratio 6.9); most thrombotic events occur 7–10 days after aspirin discontinuation. 11

Dual Antiplatelet Therapy (DAPT) Management During Active Bleeding

• In patients on DAPT (aspirin + a P2Y12 inhibitor), maintain aspirin and temporarily withhold only the P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor). [11][12]
• Simultaneous interruption of both aspirin and the P2Y12 inhibitor markedly accelerates stent thrombosis: median time to thrombosis is 7 days when both agents are stopped versus 122 days when only the P2Y12 inhibitor is held. [11][12]

Timing of P2Y12 Inhibitor Resumption

• Resume the withheld P2Y12 inhibitor within 5 days after successful endoscopic hemostasis to minimise stent‑thrombosis risk. [11][12]
• Ticagrelor – resume within 2–3 days (platelet function recovers in 3–5 days). 11
• Clopidogrel or prasugrel – resume within 5 days (irreversible agents require longer recovery). [11][12]

High‑Risk Stent Patients and Cardiovascular Consultation

• For patients who have experienced an acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) within the preceding 6 months, a cardiology consultation is mandatory before any DAPT modification. 13
• Risk‑stratified approach:
  
  • Very high risk (ACS/PCI < 6 weeks): maintain full DAPT even if bleeding occurs; defer elective procedures. 13
  • High risk (ACS/PCI 6 weeks – 6 months): continue aspirin, hold the P2Y12 inhibitor briefly, and resume it within 5 days. [13][12]
  • Moderate‑low risk (PCI > 6 months): apply the standard DAPT interruption protocol. 13

Pharmacogenetic Considerations with Proton‑Pump Inhibitors

• In Asian patients receiving clopidogrel together with high‑dose PPIs, up to 25 % are CYP2C19 slow metabolizers (versus < 5 % in Western populations), potentially diminishing clopidogrel’s antiplatelet effect through drug‑drug interaction. 11

Platelet‑Transfusion Pitfall

• Administering platelet transfusions to patients on antiplatelet therapy who present with GI bleeding does not reduce re‑bleeding rates and is associated with higher mortality. 12

Life‑Threatening Bleeding Algorithm (Key Steps)

All statements are derived from peer‑reviewed evidence cited above.